285 related articles for article (PubMed ID: 30051404)
21. Sex differences in the pulmonary circulation: implications for pulmonary hypertension.
Martin YN; Pabelick CM
Am J Physiol Heart Circ Physiol; 2014 May; 306(9):H1253-64. PubMed ID: 24610923
[TBL] [Abstract][Full Text] [Related]
22. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
[TBL] [Abstract][Full Text] [Related]
23. Selenoprotein P Promotes the Development of Pulmonary Arterial Hypertension: Possible Novel Therapeutic Target.
Kikuchi N; Satoh K; Kurosawa R; Yaoita N; Elias-Al-Mamun M; Siddique MAH; Omura J; Satoh T; Nogi M; Sunamura S; Miyata S; Saito Y; Hoshikawa Y; Okada Y; Shimokawa H
Circulation; 2018 Aug; 138(6):600-623. PubMed ID: 29636330
[TBL] [Abstract][Full Text] [Related]
24. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.
Cheng G; Wang X; Li Y; He L
Stem Cell Res Ther; 2017 Feb; 8(1):34. PubMed ID: 28187784
[TBL] [Abstract][Full Text] [Related]
25. Pathobiology of pulmonary arterial hypertension: understanding the roads less travelled.
Hemnes AR; Humbert M
Eur Respir Rev; 2017 Dec; 26(146):. PubMed ID: 29263173
[TBL] [Abstract][Full Text] [Related]
26. Oxidative and nitrosative signalling in pulmonary arterial hypertension - Implications for development of novel therapies.
Hansen T; Galougahi KK; Celermajer D; Rasko N; Tang O; Bubb KJ; Figtree G
Pharmacol Ther; 2016 Sep; 165():50-62. PubMed ID: 27216365
[TBL] [Abstract][Full Text] [Related]
27. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
Wang X; Yang Y; Yang D; Tong G; Lv S; Lin X; Chen C; Dong W
J Vasc Surg; 2016 Nov; 64(5):1468-1477. PubMed ID: 26527422
[TBL] [Abstract][Full Text] [Related]
28. CCL5 deficiency rescues pulmonary vascular dysfunction, and reverses pulmonary hypertension via caveolin-1-dependent BMPR2 activation.
Nie X; Tan J; Dai Y; Liu Y; Zou J; Sun J; Ye S; Shen C; Fan L; Chen J; Bian JS
J Mol Cell Cardiol; 2018 Mar; 116():41-56. PubMed ID: 29374556
[TBL] [Abstract][Full Text] [Related]
29. New horizons in pulmonary arterial hypertension therapies.
Galiè N; Ghofrani AH
Eur Respir Rev; 2013 Dec; 22(130):503-14. PubMed ID: 24293466
[TBL] [Abstract][Full Text] [Related]
30. Pulmonary Arterial Hypertension in Women.
Memon HA; Park MH
Methodist Debakey Cardiovasc J; 2017; 13(4):224-237. PubMed ID: 29744015
[TBL] [Abstract][Full Text] [Related]
31. Endothelin-1 receptor antagonists in fetal development and pulmonary arterial hypertension.
de Raaf MA; Beekhuijzen M; Guignabert C; Vonk Noordegraaf A; Bogaard HJ
Reprod Toxicol; 2015 Aug; 56():45-51. PubMed ID: 26111581
[TBL] [Abstract][Full Text] [Related]
32. The Search for Disease-Modifying Therapies in Pulmonary Hypertension.
Woodcock CC; Chan SY
J Cardiovasc Pharmacol Ther; 2019 Jul; 24(4):334-354. PubMed ID: 30773044
[TBL] [Abstract][Full Text] [Related]
33. The influence of gender on the development of pulmonary arterial hypertension.
Dempsie Y; MacLean MR
Exp Physiol; 2013 Aug; 98(8):1257-61. PubMed ID: 23625955
[TBL] [Abstract][Full Text] [Related]
34. 4,4'-Methylenedianiline Alters Serotonergic Transport in a Novel, Sex-Specific Model of Pulmonary Arterial Hypertension in Rats.
Carroll-Turpin M; Hebert V; Chotibut T; Wensler H; Krentzel D; Varner KJ; Burn BR; Chen YF; Abreo F; Dugas TR
Toxicol Sci; 2015 Sep; 147(1):235-45. PubMed ID: 26116029
[TBL] [Abstract][Full Text] [Related]
35. Endothelin-Bone morphogenetic protein type 2 receptor interaction induces pulmonary artery smooth muscle cell hyperplasia in pulmonary arterial hypertension.
Maruyama H; Dewachter C; Belhaj A; Rondelet B; Sakai S; Remmelink M; Vachiery JL; Naeije R; Dewachter L
J Heart Lung Transplant; 2015 Mar; 34(3):468-78. PubMed ID: 25447587
[TBL] [Abstract][Full Text] [Related]
36. Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension.
Thenappan T; Chan SY; Weir EK
Am J Physiol Heart Circ Physiol; 2018 Nov; 315(5):H1322-H1331. PubMed ID: 30141981
[TBL] [Abstract][Full Text] [Related]
37. Rapamycin reduced pulmonary vascular remodelling by inhibiting cell proliferation via Akt/mTOR signalling pathway down-regulation in the carotid artery-jugular vein shunt pulmonary hypertension rat model.
Ma X; Yao J; Yue Y; Du S; Qin H; Hou J; Wu Z
Interact Cardiovasc Thorac Surg; 2017 Aug; 25(2):206-211. PubMed ID: 28475806
[TBL] [Abstract][Full Text] [Related]
38. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?
Seferian A; Simonneau G
Eur Respir Rev; 2013 Sep; 22(129):217-26. PubMed ID: 23997048
[TBL] [Abstract][Full Text] [Related]
39. Tenascin-C is induced by mutated BMP type II receptors in familial forms of pulmonary arterial hypertension.
Ihida-Stansbury K; McKean DM; Lane KB; Loyd JE; Wheeler LA; Morrell NW; Jones PL
Am J Physiol Lung Cell Mol Physiol; 2006 Oct; 291(4):L694-702. PubMed ID: 16782755
[TBL] [Abstract][Full Text] [Related]
40. At the X-Roads of Sex and Genetics in Pulmonary Arterial Hypertension.
Cirulis MM; Dodson MW; Brown LM; Brown SM; Lahm T; Elliott G
Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33233517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
